Wrtiting of the clinical trial protocol “Psilocybin versus ketamine – a rapid antidepressant response strategy in treatment-resistant depression”

Throughout 2018, the study protocol was prepared, approved by the ethics committee and first submitted to the State Institute for Drug Control (SUKL). The project was returned for revision, mainly due to the requirements for pharmacological documentation and preparation of the final dosage form, in other words what substance, from whom and in what quality […]

Throughout 2018, the study protocol was prepared, approved by the ethics committee and first submitted to the State Institute for Drug Control (SUKL). The project was returned for revision, mainly due to the requirements for pharmacological documentation and preparation of the final dosage form, in other words what substance, from whom and in what quality will be used in the study and how capsules or tablets will be prepared from them.


Newsletter

Receive news about foundation activities and about news from the research of psychedelics.